Daniel D. Burgess
Independent Chairman of the BoardMr. Daniel D. Burgess, also known as Dan, is Director of Silver Creek Pharmaceuticals, Inc. from September 2026. He is Director of Therini Bio, Inc. Mr. Burgess serves as Chairman and Chief Executive Officer at Pulmocide Ltd since May 2021. Mr. Burgess had been an Independent Director of Cidara Therapeutics, Inc. since April 2014 until January 7, 2026. Mr. Burgess served as Chairman of the Board at Cidara Therapeutics, Inc since June 17, 2019 until January 7, 2026. He has been a Venture Partner of SV Health Investors, LLC since June 2, 2014. He serves as Venture partner at SV7 Impact Medicine Fund LP. He focuses on Therapeutics. Mr. Burgess joined SV Life Sciences Advisers, LLC on June 2, 2014. He has executive level experience in the biotechnology and pharmaceutical industries. He is a part of SV Life Sciences Advisers, LLC's Therapeutics investment team. He is also the Director of a number of DDF portfolio companies. He is an Entrepreneur and Business Leader. He founded Rempex Pharmaceuticals, Inc. in 2011 and served as its Chief Executive Officer and President from June 2011 to December 2013. Mr. Burgess was a Member of Supervisory Board of Nabriva Austria and served as its Chairman from October 2016 until the Redomiciliation. As part of his work with SV. Mr. Burgess has been acting as the Chief Executive Officer of Therini Bio, Inc. from May 2019 to December 2021. He served as the President and Chief Executive Officer of Mpex Pharmaceuticals from 2007 until its acquisition by Aptalis Inc. in 2011. From December 2013 to June 2014, he ran the Rempex subsidiary of The Medicines Company. He served as the President and Chief Executive Officer of Tripex Pharmaceuticals. He served as the Chief Operating Officer and Chief Financial Officer of Harbor Diversified, Inc. from August 1999 to May 7, 2007. He served as the Chief Financial Officer of Nanogen Inc. from 1998 to 1999 and served as its Vice President. Previously. Mr. Burgess was Chief Operating Officer and Chief Financial Officer of Harbor BioSciences, Inc. Prior to joining Nanogen in 1998, he served for many years with Sicor Inc. and Gensia Automedics Inc. He served as the President of Gensia Automedics and was responsible for all functional areas of this medical products company. He served as the Chief Operating Officer and Chief Financial Officer of Hollis-Eden Pharmaceuticals from 1999 to 2007. He served as the Chief Financial Officer and Vice President of Gensia Sicor. Prior to Hollis-Eden. Mr. Burgess spent many years with Gensia Sicor, Inc. (acquired by Teva Pharmaceutical Industries Limited) where he held a variety of executive level positions with responsibility for overall finance for it as well as a number of different operating units. He began his career at Castle & Cooke and Smith Barney, Harris Upham and Company. He serves as an Independent Chairman of the Board at Nabriva Therapeutics plc. He has been the Chairman at Atox Bio Inc. since December 15, 2014 and served as Chairman BIOCOM, Inc. since February 27, 2017 and serves as its Director. He has been the Chairman of Supervisory Board at Nabriva Therapeutics GmbH since October 21, 2016 and its Member of Supervisory Board since August 25, 2016. He serves as a Board Observer for Thesan Pharmaceuticals. He had been Independent Director of Arbutus Biopharma Corporation since March 23, 2017 until February 25, 2025. He joined the Arbutus Biopharma Corporation on March 23, 2017. He has been an Independent Director of Metabasis Therapeutics, Inc., since March 2004. He had been a Director of Avalyn Pharma, Inc. (formerly known as Genoa Pharmaceuticals, Inc.) since January 2012. He has been Independent Director of Nabriva Therapeutics plc since June 23, 2017. He serves on the Board of K2 Therapeutics. He served as a Director of Arsanis, Inc. from August 2015 to September 27, 2017. Mr. Burgess is also Chairman of the Joint Oversight Board of CARB-X. He served as a Director of Santarus, Inc. from July 2004 until its acquisition in June 2, 2014 by Salix Pharmaceuticals Incorporated. He served as a Director at Rempex Pharmaceuticals, Inc. and Gensia Automedics. Mr. Burgess holds a BA in Economics from Stanford University and an MBA from Harvard Business School (Harvard University). Mr. Burgess has B.A. in Economics from Stanford University. Mr. Burgess has M.B.A. from Harvard Business School.
Positions
- Company NameNabriva Therapeutics plcStock CodeNBRVFPositionIndependent Chairman of the Board
